Use of GLP-1 receptor agonists in patients with T2DM and chronic kidney disease

被引：1

作者：

Aldrich, Sarah ^{[1
]}

Ashjian, Emily ^{[2
]}

机构：

[1] Univ Toledo, Coll Pharm & Pharmaceut Sci, 2801 W Bancroft St, Toledo, OH 43606 USA

[2] Univ Michigan, Coll Pharm, 428 Church St, Ann Arbor, MI 48109 USA

来源：

NURSE PRACTITIONER | 2019年 / 44卷 / 03期

关键词：

chronic kidney disease; diabetes; dialysis; dulaglutide; end-stage renal disease; exenatide; glucagon-like peptide-1 receptor agonist; liraglutide; lixisenatide; semaglutide; type 2 diabetes mellitus; CARDIOVASCULAR OUTCOMES; TYPE-2; RISK; EXENATIDE; SAFETY; PHARMACOKINETICS; LIXISENATIDE; TOLERABILITY; DULAGLUTIDE; MORTALITY;

D O I：

10.1097/01.NPR.0000553396.65976.bb

中图分类号：

R47 [护理学];

学科分类号：

1011 ;

摘要：

Diabetes mellitus is the leading cause of chronic kidney disease (CKD) in the US. An increasing number of glucagon-like peptide-1 receptor agonists are available for diabetes management. Differences between medications in this class, as well as limited data on patients with CKD, underscore the importance of a patient-centered approach to care.

引用

页码：20 / 28

页数：9

共 50 条

[1] GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
Neumiller, Joshua J.
Alicic, Radica Z.
Tuttle, Katherine R.
KIDNEY AND DIALYSIS, 2022, 2 (03): : 386 - 398
[2] Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
Bahtiyar, Gul
Pujals-Kury, Jean
Sacerdote, Alan
CURRENT DIABETES REPORTS, 2018, 18 (10)
[3] Emerging GLP-1 receptor agonists
Lund, Asger
Knop, Filip K.
Vilsboll, Tina
EXPERT OPINION ON EMERGING DRUGS, 2011, 16 (04) : 607 - 618
[4] Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
Gül Bahtiyar
Jean Pujals-Kury
Alan Sacerdote
Current Diabetes Reports, 2018, 18
[5] GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art
Nauck, Michael A.
Quast, Daniel R.
Wefers, Jakob
Meier, Juris J.
MOLECULAR METABOLISM, 2020, 46
[6] The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice
von Scholten, Bernt Johan
Kreiner, Frederik Flindt
Rasmussen, Soren
Rossing, Peter
Idorn, Thomas
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2022, 13
[7] GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
Kawanami, Daiji
Takashi, Yuichi
FRONTIERS IN PHARMACOLOGY, 2020, 11
[8] Treatment of Type 2 Diabetes mellitus (T2DM): Can GLP-1 Receptor Agonists fill in the gaps?
Sharma, Smriti
Bhatia, Vinayak
CHEMICAL BIOLOGY LETTERS, 2020, 7 (04): : 215 - 224
[9] Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes
Trujillo, Jennifer
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2020, 45 : 43 - 60
[10] GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
Abasheva, Daria
Ortiz, Alberto
Fernandez-Fernandez, Beatriz
CLINICAL KIDNEY JOURNAL, 2024, 17 : 19 - 35

← 1 2 3 4 5 →